Sugi Predict

Sugi Predict / Compounds / SCHEMBL2074095

SCHEMBL2074095

SCHEMBL2074095

CCC(=O)c1ccc(F)c(C(F)(F)F)c1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ TAS1R3 Q7RTX0 2/20 0.49
▸ TAS1R1 Q7RTX1 2/20 0.49
▸ TAS1R2 Q8TE23 2/20 0.49
▸ MAPT P10636 2/20 0.48
▸ ALDH1A1 P00352 1/20 0.47
▸ HPGD P15428 1/20 0.47
▸ TSHR P16473 1/20 0.47
▸ HDAC8 Q9BY41 1/20 0.45
▸ VNN1 O95497 6/20 0.44
▸ KIF11 P52732 1/20 0.44
▸ KCNQ3 O43525 1/20 0.44
▸ KCNQ2 O43526 1/20 0.44
▸ KCNE1 P15382 1/20 0.44
▸ KCNQ1 P51787 1/20 0.44
▸ GAA P10253 1/20 0.43
▸ ATM Q13315 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31073539 0.87 HPGD (0.50) TAS1R3TAS1R1TAS1R2MAPTALDH1A1
SCHEMBL8374038 0.86 KIF11 (0.55) MAPTALDH1A1HPGDTSHRKIF11
SCHEMBL5430185 0.84 TAS1R3 (0.47) TAS1R3TAS1R1TAS1R2HDAC8VNN1
SCHEMBL2063413 0.83 TAS1R3 (0.46) TAS1R3TAS1R1TAS1R2HDAC8VNN1
SCHEMBL5312305 0.83 TAS1R3 (0.49) TAS1R3TAS1R1TAS1R2ALDH1A1HDAC8
SCHEMBL27452478 0.83 ALDH1A1 (0.49) MAPTALDH1A1HPGDTSHRATM
SCHEMBL129133 0.83 PTPN1 (0.56) TAS1R3TAS1R1TAS1R2HDAC8VNN1
SCHEMBL30129534 0.83 PTPN1 (0.56) TAS1R3TAS1R1TAS1R2HDAC8VNN1
SCHEMBL20702651 0.81 NPFFR2 (0.50) MAPTALDH1A1GAA
Hydrochloric Acid SCHEMBL311436 0.81 TAS1R3 (0.45) TAS1R3TAS1R1TAS1R2HDAC8VNN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109810573-A Inorganic nano material prints ink and its preparation method and application TCL集团股份有限公司 2019-05-28 — — CN claimed
US-12258323-B2 Dihydrooxadiazinones BAYER AKTIENGESELLSCHAFT (DE) 2025-03-25 — — US disclosed
CN-111212647-B Dihydro oxadiazinones 拜耳股份有限公司 2024-05-14 — — CN disclosed
US-11773070-B2 Dihydrooxadiazinones BAYER AKTIENGESELLSCHAFT (DE) 2023-10-03 — — US disclosed
EP-3661517-B1 DIHYDROOXADIAZINONES BAYER AG (DE) 2023-09-13 — — EP disclosed
US-20230017200-A1 DIHYDROOXADIAZINONES BAYER AKTIENGESELLSCHAFT (DE) 2023-01-19 — — US disclosed
US-20220396554-A1 DIHYDROOXADIAZINONES BAYER AKTIENGESELLSCHAFT (DE) 2022-12-15 — — US disclosed
US-11427553-B2 Dihydrooxadiazinones BAYER AKTIENGESELLSCHAFT (DE) 2022-08-30 — — US disclosed
US-20200369633-A1 DIHYDROOXADIAZINONES BAYER AKTIENGESELLSCHAFT (DE) 2020-11-26 — — US disclosed
WO-2020157188-A1 DIHYDROOXADIAZINONES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES BAYER AKTIENGESELLSCHAFT (DE) 2020-08-06 — — WO disclosed
US-20110059951-A1 HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS INCYTE CORPORATION 2011-03-10 — — US disclosed
CN-101977908-A (pyrazolyl carbonyl) imidazolidinone derivatives for the treatment of retroviral diseases AICURIS GMBH & CO KG 2011-02-16 — — CN disclosed
US-7863444-B2 4-aminopyrrolopyrimidines as kinase inhibitors ABBOTT LABORATORIES (US) 2011-01-04 — — US disclosed
CN-101522625-A Chemical compounds PRAECIS PHARM INC (US) 2009-09-02 — — CN disclosed
US-20090192206-A1 MERCAPTOIMIDAZOLES AS CCR2 RECEPTOR ANTAGONISTS VAN LOMMEN GUY ROSALIA EUGEEN 2009-07-30 — — US disclosed
US-7511068-B2 Mercaptoimidazoles as CCR2 receptor antagonists JANSSEN PHARMACEUTICA, N.V. (BE) 2009-03-31 — — US disclosed
WO-2007062308-A2 HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-05-31 — — WO disclosed
US-20060058289-A1 Mercaptoimidazoles as ccr2 receptor antagonists JANSSEN PHARMACEUTICA, N.V. (BE) 2006-03-16 — — US disclosed
WO-2004069809-A1 MERCAPTOIMIDAZOLES AS CCR2 RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2004-08-19 — — WO disclosed
CN-1326457-A 4-aminopyrrolopyrimidines as kinase inhibitors BASF AG (DE) 2001-12-12 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200369633-A1 DIHYDROOXADIAZINONES CCND2, CCNT2, CCND1 TAS1R3 4633/4885TAS1R1 4443/4885TAS1R2 4547/4885
US-20060058289-A1 Mercaptoimidazoles as ccr2 receptor antagonists CCR2, CCR5, CXCR3 TAS1R3 425/4885TAS1R1 317/4885TAS1R2 286/4885
US-11773070-B2 Dihydrooxadiazinones CCND2, DPYD, DHPS TAS1R3 4623/4885TAS1R1 4447/4885TAS1R2 4529/4885
US-20220396554-A1 DIHYDROOXADIAZINONES CCND2, DPYD, DHPS TAS1R3 4623/4885TAS1R1 4447/4885TAS1R2 4529/4885
US-20110059951-A1 HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS JAK3, JAK1, JAK2 TAS1R3 1502/4885TAS1R1 2138/4885TAS1R2 2114/4885
US-12258323-B2 Dihydrooxadiazinones CCND2, CCNT2, CCND1 TAS1R3 4633/4885TAS1R1 4443/4885TAS1R2 4547/4885
US-20230017200-A1 DIHYDROOXADIAZINONES CCND2, CCNT2, CCND1 TAS1R3 4633/4885TAS1R1 4443/4885TAS1R2 4547/4885
US-20090192206-A1 MERCAPTOIMIDAZOLES AS CCR2 RECEPTOR ANTAGONISTS CCR2, CCR1, CXCR3 TAS1R3 689/4885TAS1R1 506/4885TAS1R2 908/4885
US-11427553-B2 Dihydrooxadiazinones CCND2, CCNT2, CCND1 TAS1R3 4633/4885TAS1R1 4443/4885TAS1R2 4547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.